Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow grows, but more slowly than its trailing trend

Q1 FY2026 financing cash flow of $26.7M rose 228.2% year over year, behind the +520.7% change in trailing-twelve-month financing cash flow. Sequentially, it rose 80.4% from the prior quarter. Over 3 fiscal years it compounded at -5.8% a year.

Context

  • Financing cash flow amounted to 178.9% of revenue in FY2025, up 129.8 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +228.2% toward the trailing-twelve-month pace of +520.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$26.7M+80.4% QoQ
Last fiscal yearDec 2025
$70.75M+149.3% YoY
LTMMar 2026
$89.31M+520.7% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+228.2%——
1 year+149.3%——
3-year CAGR-5.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
70.75M USD
Year-over-year change
+149.3%
4-year CAGR
+21.1%

Financing Cash Flow vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +520.7% is the 4th highest of 11, against a peer median of +153.6%.
  • Financing cash flow amounts to 258.5% of revenue for SGMO, versus a peer median of 385.8%.
SGMO Competitors
Financing Cash Flow for SGMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVVDInvivyd, Inc.LTM Mar 2026$215.52M USD+89700.8%+652.5%385.8%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$180.48M USD+300903.0%+202.6%10116.9%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$126.91M USD+1085.3%+379.4%364.0%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$89.31M USD+520.7%-5.8%258.5%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$44M USD+352.1%+11.6%1388.6%
OABIOmniAb, Inc.LTM Mar 2026$27.87M USD+110.1%-36.8%96.4%
CDXSCodexis, Inc.LTM Mar 2026$26.83M USD-17.0%—34.4%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$24.21M USD-50.6%-7.8%1242.3%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$16.27M USD+62.5%-16.5%549.9%
IPHAInnate Pharma S.A.FY2025€5.83M EUR+197.0%—209.2%
MOLNMolecular Partners AGLTM Mar 2026CHF 1.3M CHF-109.0%-9.9%—
Peer median (excluding SGMO) —+153.6%+1.9%385.8%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(178.3M)(192.28M)(257.83M)(97.94M)(122.93M)
Depreciation & Amortization17.64M20.56M22.19M9.36M7.6M
Deferred Income Tax2.77M0(6.34M)00
Stock-Based Compensation32.96M31.65M27.36M12.38M9.08M
Change in Working Capital(101.9M)(82.32M)(164.03M)4.51M(4.22M)
Accounts Receivables(789K)2.34M(976K)953K155K
Inventory7.66M0000
Accounts Payables(7.66M)13.35M5.59M(14.17M)2.79M
Other Working Capital(101.11M)(98M)(168.65M)17.72M(7.17M)
Other Non-Cash Items(6.43M)(1.24M)153.8M4.55M13.27M
Operating Cash Flow(233.25M)(223.63M)(224.84M)(67.14M)(97.21M)
Capital Expenditures(23.28M)(20.17M)(21.16M)(267K)(102K)
Acquisitions (Net)(119K)(79.46M)01.95M0
Purchases of Investments(338.16M)(277.39M)(59.55M)00
Sales of Investments609.76M356.85M234.24M35.84M0
Other Investing Activities079.46M000
Investing Cash Flow248.2M59.29M153.53M37.52M(102K)
Debt Repayment00000
Common Stock Issued27.1M84.87M15.11M28.99M74.01M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.76M(209K)(518K)(614K)(3.26M)
Financing Cash Flow32.86M84.66M14.59M28.38M70.75M
Effect of Forex Changes(263K)1.25M1.48M(2.05M)4.09M
Net Change in Cash47.54M(78.43M)(55.24M)(3.29M)(22.47M)
Free Cash Flow(256.53M)(243.8M)(246M)(67.41M)(97.31M)

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.